U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499635) titled 'Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms' on March 24.
Brief Summary: Inhibitory immune receptors, including CD85d and CD305 (LAIR-1), act as immune checkpoint-like molecules. They contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit SH2-domain phosphatases (e.g., SHP-1), which suppress cellular activation (7,8).
CD85d is predominantly expressed in myeloid cells, including monocytes, macrophages, dendritic cells, and granulocytes. It is also differentially expressed on NK, T, B cells, and neutrophils. It is expressed at high levels in tumor cells, facilitating immune escap...